Péter Tátrai (Peter Tatrai)

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 10

Top Venues

Pharmaceutics

Drug metabolism and disposition: the biological fate of chemicals

Cancers

International journal of molecular sciences

Solvo Biotechnology (Hungary)

Semmelweis University (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Solvo Biotechnology (Hungary)

Hungary

senior scientist :: Research & Development Lab

Cancer Research UK Cambridge Institute

United Kingdom

postdoctoral researcher

Hungarian National Blood Transfusion Service

Hungary

postdoctoral researcher

Semmelweis University

Hungary

research assistant :: 2nd Department of Pathology

Education History

Semmelweis University

Hungary

PHD :: 1st Department of Pathology and Experimental Cancer Research

Eötvös Loránd University

Hungary

MSC :: Faculty of Sciences, Department of Biology

Publications

Péter Tátrai, Csilla Temesszentandrási-Ambrus, Tamás Varga, Zsuzsanna Gáborik
The inhibitor preincubation effect is universal to SLC transporter assays and is only partially eliminated in the presence of extracellular protein . Drug metabolism and disposition: the biological fate of chemicals (2023)
Gábor Petővári, Gábor Tóth, Lilla Turiák, Anna L Kiss, Krisztina Pálóczi, Anna Sebestyén, Adrián Pesti, András Kiss, Kornélia Baghy, Katalin Dezső, Tibor Füle, Péter Tátrai, Ilona Kovalszky, Andrea Reszegi
Dynamic Interplay in Tumor Ecosystems: Communication between Hepatoma Cells and Fibroblasts. International journal of molecular sciences 24 (18) (2023)
Péter Tátrai, Franciska Erdő, Péter Krajcsi
Role of Hepatocyte Transporters in Drug-Induced Liver Injury (DILI)-In Vitro Testing. Pharmaceutics 15 (1) (2022)
Péter Tátrai, Franciska Erdő, Péter Krajcsi
Role of Hepatocyte Transporters in Drug-Induced Liver Injury (DILI)-In Vitro Testing. Pharmaceutics 15 (1) (2022)
Péter Tátrai, Franciska Erdő, Péter Krajcsi
Role of Hepatocyte Transporters in Drug-Induced Liver Injury (DILI)-In Vitro Testing. Pharmaceutics 15 (1) (2022)
Péter Tátrai, Franciska Erdő, Péter Krajcsi
Role of Hepatocyte Transporters in Drug-Induced Liver Injury (DILI)-In Vitro Testing. Pharmaceutics 15 (1) (2022)
Andrea Reszegi, Katalin Karászi, Gábor Tóth, Kristóf Rada, Lórand Váncza, Lilla Turiák, Zsuzsa Schaff, András Kiss, László Szilák, Gábor Szabó, Gábor Petővári, Anna Sebestyén, Katalin Dezső, Eszter Regős, Péter Tátrai, Kornélia Baghy, Ilona Kovalszky
Overexpression of Human Syndecan-1 Protects against the Diethylnitrosamine-Induced Hepatocarcinogenesis in Mice. Cancers 13 (7) (2021)
Péter Hollósi, Lórand Váncza, Katalin Karaszi, Katalin Dobos, Bálint Péterfia, Enikő Tátrai, Péter Tátrai, Tibor Szarvas, Sándor Paku, László Szilák, Ilona Kovalszky
Syndecan-1 Promotes Hepatocyte-Like Differentiation of Hepatoma Cells Targeting Ets-1 and AP-1. Biomolecules 10 (10) (2020)
Péter Tátrai, Péter Krajcsi
Prediction of Drug-Induced Hyperbilirubinemia by In Vitro Testing. Pharmaceutics 12 (8) (2020)
Péter Tátrai, Patrick Schweigler, Birk Poller, Norbert Domange, Roelof de Wilde, Imad Hanna, Zsuzsanna Gáborik, Felix Huth
A Systematic In Vitro Investigation of the Inhibitor Preincubation Effect on Multiple Classes of Clinically Relevant Transporters. Drug metabolism and disposition: the biological fate of chemicals 47 (7) (2019)

Péter Tátrai.css-eqlu8i{font-size:small;padding-left:4px;} (Peter Tatrai)

Publication Activity (10 Years)

Top Topics

Top Venues

Péter Tátrai (Peter Tatrai)